Ex vivo-expanded highly pure ABCB5(+) mesenchymal stromal cells as Good Manufacturing Practice-compliant autologous advanced therapy medicinal product for clinical use: process validation and first in-human data

BACKGROUND AIM: Mesenchymal stromal cells (MSCs) hold promise for the treatment of tissue damage and injury. However, MSCs comprise multiple subpopulations with diverse properties, which could explain inconsistent therapeutic outcomes seen among therapeutic attempts. Recently, the adenosine triphosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerstan, Andreas, Niebergall-Roth, Elke, Esterlechner, Jasmina, Schröder, Hannes M., Gasser, Martin, Waaga-Gasser, Ana M., Goebeler, Matthias, Rak, Katrin, Schrüfer, Philipp, Endres, Sabrina, Hagenbusch, Petra, Kraft, Korinna, Dieter, Kathrin, Ballikaya, Seda, Stemler, Nicole, Sadeghi, Samar, Tappenbeck, Nils, Murphy, George F., Orgill, Dennis P., Frank, Natasha Y., Ganss, Christoph, Scharffetter-Kochanek, Karin, Frank, Markus H., Kluth, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310651/
https://www.ncbi.nlm.nih.gov/pubmed/33011075
http://dx.doi.org/10.1016/j.jcyt.2020.08.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310651/
https://www.ncbi.nlm.nih.gov/pubmed/33011075
http://dx.doi.org/10.1016/j.jcyt.2020.08.012

Ejemplares similares